Skip to content

Randomized controlled trial to evaluate the efficacy of exercise training on cognitive function in peritoneal dialysis patients

Randomized controlled trial to evaluate the efficacy of exercise training on cognitive function in peritoneal dialysis patients - Exercise training in peritoneal dialysis patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000040271
Enrollment
60
Registered
2020-04-30
Start date
2020-06-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Peritoneal dialysis patients

Interventions

24-week home-based exercise training, including 20-30 minutes of aerobic exercise thrice-weekly and resistance training twice-weekly. Exercise intensity is determined by the result of major muscle tes

Sponsors

Division of Endocrinology, Metabolism and Nephrology, Department of Internal Medicine, Keio University, School of Medicine
Lead Sponsor
Department of Nephrology, International University of Health and Welfare, School of Medicine
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Peritoneal dialysis outpatients. 2) Patients from whom written informed consent was obtained.

Exclusion criteria

Exclusion criteria: 1) Patients who are contraindicated for exercise training. Concrete criteria are as follows: patients with uncontrolled persistent hypertension (systolic blood pressure >= 180 mmHg or diastolic pressure >= 110 mmHg); severe anemia (Hb < 7 g/dL); active proliferative diabetic retinopathy; prior symptomatic coronary artery or cerebrovascular diseases within the previous 3 months; uncontrolled heart failure (NYHA >= III); symptomatic or lethal arrhythmia; severe valvular diseases; and walking difficulty due to orthopedic, cerebrovascular and peripheral artery diseases. 2) Unstable PD patients. Concrete criteria are as follows: patients who undergo PD less than 3 months and those with uncontrolled uremia (BUN > 100 mg/dL, K > 6.0 mEq/L and HCO3 < 18 mmoL/L). 3) Patients deemed inadequate for monitoring during study period, as determined by investigators.

Design outcomes

Primary

MeasureTime frame
Cognitive function assessed by Japanese version of the Montreal Cognitive Assessment, evaluated 24 weeks after assignment.

Secondary

MeasureTime frame
Executive function, aerobic capacity, muscle strength, quality of life, residual renal function and parameters associated with arteriosclerosis, evaluated 24 weeks after assignment.

Countries

Japan

Contacts

Public ContactRyunosuke Mitsuno

Department of internal medicine, Keio University, School of Medicine Division of Endocrinology, Metabolism and Nephrology

rmitsuno@keio.jp+81-3-3353-1211(0535)

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026